PubMed Health⌕ Search

PubMed · 3184786

[Preoperative plasmapheresis].

Abstract

Plasmapheresis is performed during the preoperative patient preparation phase of the Ulm Autologous Transfusion Concept (ATU). On an outpatient basis, weeks or months before the operation, 900 ml autologous plasma is donated per visit using the one needle technique, shock frozen, and stored at -30 degrees C or lower. During a period of approximately 1 1/4 years, 813 patients were studied in order to obtain information (in addition to the observation of the usual vital statistics) concerning the effect of plasmapheresis on homeostasis and coagulation factors directly before, directly after, 2 h after, and 24 h after (in-patients only). A complete electrolyte solution of the Ringer-lactate type was used as volume substitution (1000 ml or 1500 ml). Arterial blood pressure and heart rate showed no significant change. The transient decrease in various laboratory parameters was within tolerable limits. The parameters for blood protein, anti-thrombin III, and immunoglobulin G had already normalized within 24 h. Our more than three year experience with more than 2600 patients and the collective data indicate no reason not to perform plasmapheresis on non-fasting outpatient patients. The for the most part postoperatively transfused autologous fresh frozen plasma represents an ideal, long acting volume substitution which contains such blood components as antithrombin III, immunoglobulins, and factor XIII. These blood components could be a contributing factor for a decreased danger of thrombosis, embolie, and infection, as well as provide for better wound healing.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W Schleinzer, H H Mehrkens, B von Bormann, M Weindler, K H Wollinsky. 1988. [Preoperative plasmapheresis].. https://pubmed.ncbi.nlm.nih.gov/3184786/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results.

In some mild haemophilia A patients (discrepant haemophilia), factor VIII coagulant activity (FVIII:C) levels, by one-stage assay are more than double than those by two-stage assay. This may be due to the longer incubation times (10-12 min) in the two-stage assay. This study aimed to determine the time course of the activation phase of the two-stage assay, using both classical coagulation and chromogenic detection methods. In both systems, for equivalent patients (equivalent FVIII:C levels by one-stage and two-stage assays, n = 6, all different mutations), similar FVIII:C results were obtained with short- or long-incubation times. In contrast, plasma from discrepant patients (n = 8, five different mutations) showed higher FVIII:C at shorter incubation times than after longer incubation times. In the chromogenic assay, FVIII:C levels were higher after incubation for 2 min (23-56%, mean 41%) than after 10 min (19-41%, mean 29%). In the classical coagulation assay, FVIII:C levels were higher at shorter incubation times (21-64%, mean 37%) than with the longer incubation times usually used (13-29%, mean 23%). These time-course experiments have verified that the longer incubation time used in the two-stage assay is at least partly responsible for the lower FVIII:C measured by that assay in discrepant haemophilia.

Blood Coagulation Tests↗

Von Willebrand disease within the collective of haemophilic patients as reason for unexpected bleeding episodes.

In the treatment of haemophilia A and B, recombinant coagulation factors are increasingly replacing plasma-derived factor VIII and IX concentrates. Although provided with replacement therapy, individual patients may exhibit bleeding episodes, which are difficult to control. These bleeds may be caused by von Willebrand disease (VWD) as an additional underlying coagulation disorder. We report in the present study our experience that in the collective of haemophilic patients, VWD must be anticipated at least with the same order of magnitude as it appears in a normal healthy population. Among the patients at our treatment centre, two patients (1.5%) were identified as suffering from VWD in addition to haemophilia A. In the collective of haemophilia B patients at our centre, three patients (10%) with VWD were found. Two of these patients exhibited unexpected severe bleeding episodes, which could only satisfactorily be controlled by the administration of Haemate-P or DDAVP supplementary to the recombinant coagulation factor concentrate.

Blood Coagulation Tests↗